We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Manufacturing violations cited in a June 15 FDA warning letter to Ranbaxy Laboratories could result in a hold on some of the company’s new drug applications (NDAs) and a U.S. ban on importation its products.